Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 14, 2020

Primary Completion Date

February 18, 2021

Study Completion Date

February 18, 2021

Conditions
COVID-19
Interventions
DRUG

FT516

FT516 is an off-the-shelf cryopreserved NK cell product derived from an iPSC that was transduced with a high affinity, ADAM17 non-cleavable CD16 (Fc receptor) that maintains CD16 on the cell surface, which remains fully functional after NK cell activation.

Trial Locations (1)

55455

University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT04363346 - Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia | Biotech Hunter | Biotech Hunter